Valneva's 15-min chart triggers KDJ Golden Cross, Bullish Marubozu Formation

Valneva's 15-minute chart has exhibited a significant bullish trend, as evidenced by the KDJ Golden Cross and Bullish Marubozu pattern observed on August 26, 2022, at 12:30. This indicates a shift in the momentum of the stock price towards the upside, with a potential for further growth. The bullish momentum is likely to persist, as buyers continue to control the market.

Title: Valneva's 15-Minute Chart Exhibits Bullish Trend

Valneva's 15-minute chart has recently shown significant bullish indicators, with a KDJ Golden Cross and a Bullish Marubozu pattern observed on August 26, 2022, at 12:30. These technical signals suggest a shift in the stock's momentum towards an upward trajectory, indicating potential for further price appreciation. The bullish momentum is likely to persist, as buyers continue to control the market.

The KDJ Golden Cross is a bullish signal that occurs when the K-line crosses above the D-line on the KDJ indicator, signaling a change in the trend from bearish to bullish. The Bullish Marubozu candle further supports this upward trend, indicating strong buying pressure with no wick on either end of the candle. This combination suggests that Valneva's stock price is poised for continued growth.

Valneva's recent financial performance has been positive. The company reported a 20.8% increase in revenue to €45.993 million for the period ending June 30, 2025, according to the mean estimate from 3 analysts [1]. Despite the expected loss of 22 cents per share, the current average analyst rating on the shares is "buy," with a breakdown of recommendations as 3 "strong buy" or "buy," 1 "hold," and no "sell" [2].

However, investors should remain cautious. Technical indicators alone should not be the sole basis for investment decisions. It is essential to consider other factors, such as the company's fundamentals, earnings reports, and market conditions, when evaluating Valneva's stock.

Valneva's recent setbacks, including the FDA suspension of its chikungunya vaccine, have had a significant impact on its stock price. The suspension, which took effect immediately, is in response to four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness [3]. Despite this, Valneva's pipeline diversification with Lyme disease (VLA15) in Phase 3 and Shigella/Zika candidates, along with €161.3M in cash reserves, positions the company to hedge risks and target high-growth markets [4].

Investors should closely monitor Valneva's Phase 3 Lyme data and the outcomes of the post-marketing IXCHIQ® study to gauge the potential impact on the stock price. The company's strong cash reserves and strategic access to endemic markets provide a solid foundation for long-term growth, despite near-term risks.

References:
[1] https://www.ainvest.com/news/valneva-15min-chart-sees-kdj-golden-cross-bullish-marubozu-pattern-2508/
[2] https://www.ainvest.com/news/valneva-ixchiq-vaccine-navigating-safety-concerns-unlock-long-term-2508/
[3] https://www.ainvest.com/news/valneva-chikungunya-vaccine-sales-suspended-2508/
[4] https://www.investing.com/news/analyst-ratings/jefferies-lowers-valneva-stock-price-target-to-14-on-fda-suspension-93CH-4209311